Introduction
Multiple Sclerosis (MS) is the most common autoimmune disease of the Central Nervous System (CNS) in which a coordinated attack of the immune system against myelin takes place. 1, 2 Myelin Basic Protein (MBP), Proteolipid Protein (PLP), Myelin
Oligodendrocyte Glycoprotein (MOG) and Myelin-Associated Glycoprotein (MAG) are the main myelin proteins in the CNS and they have been recognized as putative auto-antigens for MS. 3 MS onset is triggered by the activation of the encephalitogenic T-cells through the formation of a trimolecular complex between the T-cell receptor (TCR), the peptide (antigen) -with identical residue sequence to a fragment of a protein of the myelin sheath (molecular mimicry theory) 4 , 5 -and the Major Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA). The ability of the peptide-HLA complex to activate T-cells is correlated with the strength of its binding affinity with TCR. [6] [7] [8] Conversely, stimulation or not of T-cells that are responsible for MS follows.
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The HLA class II receptors are dimers comprised of two different polypeptide chains (α and β). 14, 15 In this class of macromolecules the polypeptide chains are joined together, creating a single receptor for the antigens to bind to. Subsequently, the newly (CDRs). These domains are implicated in the recognition process between the TCR and the HLA-antigen complex. 16 The diversity of the CDRs plays a crucial role in the recognition of the different antigens as they are presented by the HLA receptors. The
CDRs comprising the TCR chains are very effective at screening the various antigens 4 presented to the T-cells. 9, 17 It has been estimated by in vivo experiments that the TCR unique structures in humans are over >2.5x10 7 . 17, 18 Despite the diverse numbers and the rigorous selection process of T-cells in the thymus, 19, 20 there are cases where the selection process fails to single out T-cells reacting to self-antigens. 21 Thus, the failure in the thymic selection leads to self-reactive T-cells and induction of autoimmune disorders such as MS. 22, 23 The myelin sheath consists of multiple proteins; MBP and PLP are two of the major component of the myelin sheath, while MOG and Myelin-associated Glycoprotein (MAG) are less abundant. 24, 25 The total myelin proteins consist of only 0.05%-0.1% of MOG; 24, 25 however MOG or MOG epitopes activate T-cell immune responses in Experimental Autoimmune Encephalomyelitis (EAE, animal model of MS) and have also been associated with MS induction. 26, 27 There have been extensive studies of different fragments of MOG as autoimmune triggers. [28] [29] [30] [31] [32] The MOG epitopes we looked at the adopted conformations by the peptide in aqueous solution, ii) we carried out MD simulation studies using hMOG35-55 in combination with HLA DR2
(DRA, DRB1*1501) receptor and iii) the created trimolecular complex between hMOG35-55, HLA DR2 and TCR was explored. The investigation of the interactions between hMOG35-55 and the receptors in the trimolecular complex is expected to provide important information on the binding patterns of the hMOG epitope, which can assist researchers in the rational design of novel molecules, focusing on the inhibition of the stimulated encephalitogenic T-cells that are responsible for EAE and MS induction. 6 
Methods
The high resolution crystal structure of HLA DR2 (DRA, DRB1 , based on the human sequence, used for the simulation studies was constructed using PyMOL. 37 During this process the amino acids (L configuration), comprising the peptide, were placed in sequential order with no initial secondary structure assignment (unfolded conformation). The different systems were subjected to all-atom unrestrained MD simulations in explicit solvent using AMBER14. 38 
Molecular Dynamics (MD) simulation of hMOG35-55
For the construction of the hMOG35-55 peptide parameters, the AMBER force field ff14SB 39 has been used. The TIP3P water model 40 was utilized for the solvation of the system and the total charge was neutralized by the addition of three Cl -ions.
Truncated octahedral periodic boundary conditions have been applied to the system with a cutoff distance of 10 Å. The next step involved the minimization, followed by the heating of the system, under constant volume, to 300K for 100ps using the Langevin dynamics temperature scaling. 41 This was followed by equilibration for another 100 ps under constant pressure. Both heating and pressure equilibration were performed using a 10 kcal mol -1 Å -2 restraint on the solute. The equilibration step under constant pressure was prolonged for a further 200 ps, after removing all restraints. The MD production run was performed under constant pressure and temperature conditions (NPT ensemble)
for 100 ns. The temperature was kept constant with the use of the Langevin thermostat (using a collision frequency of 2 ps -1 ). All bonds involving hydrogen atoms were kept 7 to their equilibrium distance with the SHAKE algorithm (allowing for a 2 fs time step to be used). 42 The long range electrostatic interactions were calculated with the Particle Mesh Ewald (PME) method. 43 
Molecular Dynamics (MD) simulation of the hMOG35-55 complexed with the HLA
DR2 receptor
The positioning of the hMOG35-55 epitope inside the HLA DR2 receptor was performed manually using PyMOL. 37 The minimized structure (Section 2. 36, 44, 45 In the next step, the residues comprising the TCR were removed along with all crystallographic water molecules.
The missing hydrogens were added using the tLeap module in AMBER14.
As with the MD simulation of hMOG35-55 in water, the parameters for the receptor were constructed using the AMBER force field ff14SB. 39 The total charge of the system was neutralized with the addition of fourteen Na + ions. The TIP3P water model 40 was used in the solvation of the system and truncated octahedral periodic boundary conditions were applied to the system with a cutoff distances of 10 Å. The system was minimized over 5000 steps, followed by the gentle heating to 300K over 100 ps, using the Langevin dynamics temperature scaling (time step 2 fs). The system was further equilibrated under constant pressure for 100 ps. As mentioned in section 2.1, both the heating and equilibration steps were performed using a 10 kcal mol -1 Å -2 restraint on the solute. A 200 ps equilibration step, under constant pressure, was performed 8 following the removal of the restraint on the solute. Finally, an MD production run for 40 ns was performed using the NPT ensemble.
Molecular Dynamics (MD) simulation of TCR-hMOG35-55-HLA DR2 complex
For the MD simulation of the hMOG35-55 epitope in complex with both TCR and HLA the construction of the system followed the same steps described in section 2.2.
The minimized conformation of the linear hMOG35-55 epitope (Section 2.1) was superimposed with the crystal structure of HLA DR2/MBP83-96/TCR). Thus, the TCR from the crystal structure was positioned over the hMOG35-55-HLA DR2 complex.
Subsequently, the MBP83-96 peptide was removed from the crystal structure along with the water molecules. The preparation of the system and the MD simulation followed the steps mentioned in section 2.2. A total of thirteen Na + ions were used to neutralize the system and the solvation of the complex in explicit solvent was done using the TIP3P water model.
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A 40 ns MD production run in the created trimolecular complex was performed using AMBER14. 38 Studies in similar biological systems show that the simulation time reported here is adequate for the conformational analysis of the bound epitope. [46] [47] [48] [49] [50] The parameters for the proteins and the peptide were constructed using the AMBER ff14SB
force field. 39 The next step involved the minimization of the system followed by the heating of the complex to 300 K for 100 ps. Constant pressure equilibration was performed for a total of 300 ps. During the first 100 ps, a 10 kcal mol -1 Å -2 restraint constant was imposed on the solute, which was then removed for the rest of the equilibration run. The MD production run was attained under isothermal and isobaric conditions and the temperature was kept constant with the use of the Langevin thermostat. The bonds involving hydrogen atoms were kept to their equilibrium 9 distance with the SHAKE algorithm. 42 The Particle Mesh Ewald (PME) method 43 was implemented for the calculation of the long range electrostatic interactions. Following, the above procedure, we also performed two MD simulations with mutated forms of hMOG35-55, namely: hMOG35-55(Ala 41 ) and hMOG35-55(Ala 41, 46 ). In these variants, the Arg was replaced by Ala in position 41 and in positions 41/46, respectively.
Trajectory and Clustering analysis
The analysis (Rms deviations, atomic fluctuations and clustering calculations) of all the AMBER MD trajectories, was carried out using the cpptraj module 51 of the AMBER14 molecular package. The analysis of the hydrogen bond (HB) interactions was based on geometrical criteria, the limitations imposed were a 3.5 Å cutoff for donor-acceptor distance and a donor-hydrogen-acceptor angle cutoff of 120°. For the clustering analysis of the various MD trajectories, the hierarchical method 52 was used in the grouping process, with the Rms being the distance metric (cutoff 2.0 Å). The representative conformations presented in the paper are snapshots taken from the reference (centroid) simulation frames, used during the clustering analysis by the cpptraj module.
Results
Conformational characteristics of hMOG35-55 epitope
The analysis of the MD trajectory for the hMOG35-55 in solution revealed that hMOG35-55 does not retain an extended form. The different conformations adopted throughout the 100 ns trajectory, showed that the dominant form of the peptide presents two bends (Figure 1a ). The particular conformation is displayed on approximately 40%
of the simulation time. The bend conformation of the peptide may be partly attributed 10 to its hydrophobic content (Figure 1b , thicker ribbon). The hydrophobic residues may force the polypeptide chain to seek conformations that decrease their exposure to the solvent. As expected, the small length does not allow the peptide to adopt a more stable secondary structure like α-helix or β-sheet. Instead hMOG35-55 remains in a largely unfolded state in aqueous solution, in accordance with experimental observations. 53, 54 The adoption of a bend conformation by the peptide is further supported by the analysis of the secondary structures of the residues during the MD simulation ( Figure   S1 , in Supporting Information). It is evident that the secondary structure of the peptide does not present a stable conformational profile throughout the MD simulation ( Figure   S1 ). Though, it displays certain helical features, such as bends and turns ( Figure S1 , red and brown colours, respectively). These observations are in close agreement with those reported by Albouz-Abo et. al (1997) . 53 In the particular paper, Circular Dichroism 
Conformational analysis of hMOG35-55-HLA DR2 receptor complex
A visual inspection of all the conformations during the MD simulation was carried out and the amino acids of the hMOG35-55 with side chains that were oriented into the HLA DR2 main pockets were recorded ( Figure S3 ). The conformational analysis of the hMOG35-55-HLA DR2 complex showed that the peptide occupies pockets 1, 4, 6 and 9 of the receptor ( Figure S3 ). These four pockets are the same areas 
Hydrogen bond interactions in hMOG35-55-HLA DR2 receptor complex
A detailed analysis of the hydrogen bonds (HBs), between the amino acids of hMOG35-55 and the HLA DR2 receptor, was carried out and the results are presented in Table S1 in Supporting Information. c Only HBs with occurrence of more than 20% of the simulation time are presented here.
As observed in Table 1 respectively). These extensive interactions with the receptor may increase the binding affinity of the hMOG35-55.
As mentioned in section 3.1, hMOG35-55 adopts a bend conformation due to the presence of HB formed between residues such as Glu 36 and Phe 44 ( Figure 1 ). When bound to the HLA DR2 receptor, this conformational feature is not retained (Figure 2) which is expected, since the interactions between the epitope and the residues of the receptor may lead to a conformational rearrangement of the epitope in order to enhance its binding. The bend aspect of the hMOG35-55 peptide is an essential feature, because it allows the epitope to reach inside the receptor. Thus, residues such as Tyr 40 and Pro 43 may interact with residues in different pockets (P1 and P4, respectively) and create a more extensive HB network with the HLA DR2 molecule.
Conformational analysis of the trimolecular complex (TCR-hMOG35-55-HLA DR2)
As discussed in the Methods section (Section 2. (Figure 3a) .
Clustering analysis of the trimolecular complex (TCR-hMOG35-55-HLA DR2)
The clustering analysis showed that there are four representative clusters throughout the simulation (Figure 4a (Table 2) . These interactions are also present for most of the simulation time. contrast to Arg, has a very small, non-polar side chain group that subsequently may affect the potential of the peptide to interact with TCR, since the particular position is solvent exposed and thus favours the presence of hydrophilic residues. As observed with the two variants of hMOG35-55 [hMOG35-55(Ala 41 ) and hMOG35-55(Ala 41, 46 )], the mutation of Arg to Ala leads to loss of interactions between the TCR and hMOG35-55 (Table 2) , while retaining the same pattern of HBs and binding affinity towards the HLA receptor (Table 1 ). In both the hMOG35-55 and its mutations, the interactions between Phe 44 and the HLA receptor are identical in nature.
Conformation characteristics of mutated hMOG35-55(Ala
Conclusion
The peptide variants [hMOG35-55(Ala 41 ) and hMOG35-55(Ala 41, 46 )] have proved to act as inhibitors of EAE, which is the animal model for MS. 26 The information compiled during our studies confirms that the mutation of key residues in hMOG35-55 leads to competitive binding to the HLA receptor and loss of key interactions with the TCR, thus preventing the formation of the trimolecular complex. This report provides a comprehensive theory regarding the interactions and conformational changes observed in the formation of the trimolecular complex (TCR-hMOG35-55-HLA DR2 receptor) and highlights key interactions of the hMOG35-55 epitope.
